The Institute for Clinical and Economic Review(ICER) released a Draft Evidence Report assessing the comparative clinical effectiveness and value of therapies to treat tardive dyskinesia, a movement disorder often associated with long-term use of antipsychotic medications. The report, along with draft voting questions, will be open to public comment for four weeks.
ICER’s report reviews evidence on three drug treatments. Valbenazine and deutetrabenazine were both approved by the Food and Drug Administration earlier this year with an indication for tardive dyskinesia. Tetrabenazine is approved for use in Huntington’s disease and is often used to treat tardive dyskinesia, though it is not formally approved for that indication.